SOUTH SAN FRANCISCO, Calif. and BOSTON, July 8 /PRNewswire/ -- iZumi Bio, Inc. and Pierian, Inc. today announced they have merged to form a new company, iPierian, Inc. Building on the iZumi infrastructure and vision, the company is focused on the application of cellular reprogramming to change the paradigm of drug discovery. The scientific leadership of the company will accelerate the development of new therapeutics using induced pluripotent stem (iPS) cells for patients with difficult-to-treat diseases.
iPierian is rapidly building upon the experienced management and scientific team of iZumi, who have deep knowledge and experience in both stem cell technology and drug discovery. The company will be led by John P. Walker, currently the chief executive officer of iZumi. Dr. Berta Strulovici will head up research efforts as the chief technical officer of iPierian and Dr. Dushyant Pathak will lead the company's business development activities. Dr. Corey Goodman, recently the president of Pfizer's Biotherapeutics and Bioinnovation, an elected member of the U.S. National Academy of Sciences, and a board member of iZumi, will become chairman of the Board of Directors of iPierian.
The scientific founders of Pierian, Drs. George Daley, Douglas Melton and Lee Rubin, faculty members at Harvard University, will become actively involved in decisions regarding the scientific direction and research priorities for iPierian. Dr. Daley will co-chair the new Scientific Advisory Board (SAB) of iPierian together with Dr. Deepak Srivastava, director of the Gladstone Institute of Cardiovascular Disease and professor at the University of California San Francisco (UCSF). Dr. Corey Goodman will also sit on the company's SAB, and will be joined by a cadre of leading stem cell scientists.
"Since the inception of iZumi, we have built an organization and a platform of cellular programming as it applies to drug d
Page: 1 2 3 4 5 6 Related biology technology :1
|SOURCE iZumi Bio, Inc.; Pierian, Inc.|
Copyright©2009 PR Newswire.
All rights reserved
. The Gladstone Institutes and iZumi Bio Announce Broad Partnership in Regenerative Medicine and Cardiovascular Disease2
. iZumi Bio, Inc. Recruits Leading iPS Scientist, John Dimos, to Translate Stem Cell Breakthrough Into Patient Benefits3
. iZumi Bio, Inc., Appoints John Walker as Chief Executive Officer4
. iZumi Bio Appoints Dr. Berta Strulovici as Chief Technology Officer and Dr. Dushyant Pathak as Vice President of Business Development5
. iZumi Bio Appoints Dr. Corey Goodman to Board of Directors and Scientific Advisory Board6
. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.7
. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review8
. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court9
. ev3 and FoxHollow Announce Date for Special Meeting of FoxHollow Stockholders to Vote on Proposed Merger10
. IsoTis - Integra Merger11
. New Brunswick Scientific Completes Merger Transaction with Eppendorf